The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of AKB-9778 administered as
daily subcutaneous injections with and without monthly intravitreal injections of ranibizumab
for 3 months in patients with diabetic macular edema.